PE20220505A1 - Moleculas de union a tigit y pd-1/tigit - Google Patents

Moleculas de union a tigit y pd-1/tigit

Info

Publication number
PE20220505A1
PE20220505A1 PE2021001860A PE2021001860A PE20220505A1 PE 20220505 A1 PE20220505 A1 PE 20220505A1 PE 2021001860 A PE2021001860 A PE 2021001860A PE 2021001860 A PE2021001860 A PE 2021001860A PE 20220505 A1 PE20220505 A1 PE 20220505A1
Authority
PE
Peru
Prior art keywords
tigit
binding molecules
seq
chemotherapy
bind
Prior art date
Application number
PE2021001860A
Other languages
English (en)
Inventor
Naresh Kumar
James David Pancook
Stephanie Marie Truhlar
Yang Zhao
Yiqing Feng
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20220505A1 publication Critical patent/PE20220505A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se refiere a las moleculas de polipeptidos que se unen a TIGIT humano (SEQ ID NO: 31), que comprende las secuencias de aminoacidos de las SEQ ID NO: 1-6, y son utiles para tratar tumores solidos, solas y en combinacion con quimioterapia y/o radiacion ionizante.
PE2021001860A 2019-05-29 2020-05-22 Moleculas de union a tigit y pd-1/tigit PE20220505A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853816P 2019-05-29 2019-05-29
PCT/US2020/034158 WO2020242919A1 (en) 2019-05-29 2020-05-22 Tigit and pd-1/tigit-binding molecules

Publications (1)

Publication Number Publication Date
PE20220505A1 true PE20220505A1 (es) 2022-04-07

Family

ID=71070067

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001860A PE20220505A1 (es) 2019-05-29 2020-05-22 Moleculas de union a tigit y pd-1/tigit

Country Status (23)

Country Link
US (1) US20220227860A1 (es)
EP (1) EP3976652A1 (es)
JP (2) JP7241207B2 (es)
KR (1) KR20220004120A (es)
CN (1) CN113939536B (es)
AR (1) AR118980A1 (es)
AU (1) AU2020283817A1 (es)
BR (1) BR112021021795A2 (es)
CA (1) CA3139025A1 (es)
CL (1) CL2021003039A1 (es)
CO (1) CO2021015610A2 (es)
CR (1) CR20210573A (es)
DO (1) DOP2021000241A (es)
EA (1) EA202192796A1 (es)
EC (1) ECSP21085693A (es)
IL (1) IL287765A (es)
JO (1) JOP20210314A1 (es)
MA (1) MA56029A (es)
MX (1) MX2021014472A (es)
PE (1) PE20220505A1 (es)
SG (1) SG11202112725XA (es)
TW (1) TWI760751B (es)
WO (1) WO2020242919A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018127916A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A pd1-cd70 fusion protein and methods of use thereof
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
HRP20230937T1 (hr) 2017-01-05 2023-11-24 Kahr Medical Ltd. Pd1-41bbl fuzijski protein i metode korištenja istog
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
US20240076346A1 (en) * 2021-01-13 2024-03-07 Kahr Medical Ltd. Type i membrane proteins heterodimers and methods of use thereof
WO2023034336A2 (en) * 2021-08-30 2023-03-09 G1 Therapeutics, Inc. Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility
WO2023088436A1 (zh) * 2021-11-18 2023-05-25 信达生物制药(苏州)有限公司 抗pd-1抗体和抗vegf-a抗体的药物组合及其使用方法
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014290069B2 (en) * 2013-07-16 2019-01-03 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
EP3169363A4 (en) 2014-07-16 2018-02-21 F. Hoffmann-La Roche AG Methods of treating cancer using tigit inhibitors and anti-cancer agents
MA40475A (fr) * 2014-08-19 2017-06-28 Fayadat Dilman Laurence Anticorps anti-tigit
UY36471A (es) 2014-12-23 2016-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra el inmunorreceptor (tigit) de linfocitos t con dominios ig y motivos de inhibición del inmunorreceptor basados en tirosina (itim)
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
JP6764474B2 (ja) 2015-09-25 2020-09-30 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔ抗体及び使用方法
ES2774320T3 (es) 2016-08-17 2020-07-20 Compugen Ltd Anticuerpos anti-TIGIT, anticuerpos anti-PVRIG y combinaciones de los mismos
JOP20190133A1 (ar) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
EP3565839A4 (en) * 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
CA3062061A1 (en) * 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
AR112603A1 (es) * 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
CN110997720A (zh) * 2017-07-27 2020-04-10 Iteos治疗公司 抗tigit抗体
AU2018396970A1 (en) * 2017-12-28 2020-08-13 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against TIGIT
EP3813864A4 (en) * 2018-06-29 2022-07-20 Gensun Biopharma Inc. ANTITUMOR ANTAGONISTS

Also Published As

Publication number Publication date
AR118980A1 (es) 2021-11-17
TWI760751B (zh) 2022-04-11
AU2020283817A1 (en) 2021-11-25
CN113939536B (zh) 2024-05-14
MA56029A (fr) 2022-04-06
ECSP21085693A (es) 2021-12-30
BR112021021795A2 (pt) 2022-01-04
DOP2021000241A (es) 2021-12-30
EP3976652A1 (en) 2022-04-06
CL2021003039A1 (es) 2022-08-05
WO2020242919A1 (en) 2020-12-03
CN113939536A (zh) 2022-01-14
JP2023071889A (ja) 2023-05-23
JP2022533457A (ja) 2022-07-22
CR20210573A (es) 2021-12-15
EA202192796A1 (ru) 2022-03-03
JOP20210314A1 (ar) 2023-01-30
SG11202112725XA (en) 2021-12-30
CO2021015610A2 (es) 2021-11-30
IL287765A (en) 2022-01-01
CA3139025A1 (en) 2020-12-03
US20220227860A1 (en) 2022-07-21
MX2021014472A (es) 2022-01-06
TW202110884A (zh) 2021-03-16
JP7241207B2 (ja) 2023-03-16
KR20220004120A (ko) 2022-01-11

Similar Documents

Publication Publication Date Title
PE20220505A1 (es) Moleculas de union a tigit y pd-1/tigit
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
MY181106A (en) Anti-lag3 antibodies and uses thereof
ZA202002325B (en) Constrained conditionally activated binding proteins
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
EA201592006A1 (ru) Новые биспецифические связывающие молекулы с противоопухолевой активностью
ECSP19011185A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
CO2019003951A2 (es) Proteínas de unión a cd123 y composiciones y métodos relacionados
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
BR112022021884A2 (pt) Proteínas que se ligam a nkg2d, cd16 e clec12a
MY167232A (en) Polypeptides binding to human complement c5
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
BR112021025438A2 (pt) Composições de proteínas anti-vegf e métodos para produzir as mesmas
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
MX2023007067A (es) Proteinas recombinantes de union a cd3 y su uso.
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
MX2021010837A (es) Receptores en linfocitos t de la proteina 1 de tumor de wilms (wt1) de alta avidez.
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
BR112022002761A2 (pt) Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40
BR112018006820A2 (pt) anticorpos anti-psa (5a10) humanizados
MX2022003523A (es) Proteinas de union a antigenos.